Characterizing skin cancers based on their biological features
Stratification of Cutaneous Squamous Cell Carcinomas According to Its Transcriptomic, Metabolic and Inflammatory Characteristics
NA · University Hospital, Bordeaux · NCT06476964
This study is trying to see if analyzing skin samples from patients with certain skin conditions can help predict the risk of skin cancer coming back or spreading.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Bordeaux (other) |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Bordeaux) |
| Trial ID | NCT06476964 on ClinicalTrials.gov |
What this trial studies
This study aims to collect skin biopsies from patients with suspected actinic keratosis or cutaneous squamous cell carcinoma to analyze their molecular, metabolic, and immunological characteristics. By examining these features, the research seeks to identify genetic profiles that could predict the risk of recurrence and metastasis in skin cancers. The study focuses on understanding the progression from precancerous lesions to invasive cancers, which is crucial for developing better predictive tools for patient management.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and over with suspected actinic keratosis or cutaneous squamous cell carcinoma lesions.
Not a fit: Patients with previous systemic treatments or those with lesions on visible areas of the face or folds may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved risk assessment and personalized treatment strategies for patients with skin cancer.
How similar studies have performed: While there have been studies on skin cancer characteristics, this approach focusing on transcriptomic and metabolic profiling is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 or over, * Patients with suspected AK, or cSCC lesions (in situ, infiltrating or metastatic), * Patients able to sign a consent form, * Patients affiliated to a French Social Security system. Exclusion Criteria: * Patients who have previously received systemic treatment (chemotherapy, immunotherapy), * Patients with cSCC or AK localized on visible zone of the face or folds * Patients under guardianship or guardianship, * Patient not affiliated to a French Social Security system.
Where this trial is running
Bordeaux
- University Hospital of Bordeaux - Department of Dermatology — Bordeaux, France (RECRUITING)
Study contacts
- Principal investigator: Marie BEYLOT-BARRY, MD, PhD — University Hospital, Bordeaux
- Study coordinator: Marie BEYLOT-BARRY, MD, PhD
- Email: marie.beylot-barry@chu-bordeaux.fr
- Phone: +335 57 82 25 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Skin Cancer, Actinic keratosis,, Cutaneous squamous cell carcinoma, mitochondria, metabolism